Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral etoposide plus realgar natural indigo tablets and all-trans retinoic acid in high-risk acute promyelocytic leukemia
ChiCTR2100053926Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etoposide, Compound Huangdai Tablet and tretinoin in Acute promyelocytic leukaemia (APL), sponsored by Peking University People's Hospital. Primary endpoints: Remission rate and Death rate. Started Jan 2022; status: recruiting.
02
Drugs
etoposideCompound Huangdai Tablettretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2100053926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053926.